Transcat, Inc. $TRNS Stake Lowered by Conestoga Capital Advisors LLC

Conestoga Capital Advisors LLC lessened its holdings in shares of Transcat, Inc. (NASDAQ:TRNS) by 23.4% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 344,572 shares of the scientific and technical instruments company’s stock after selling 104,985 shares during the period. Conestoga Capital Advisors LLC’s holdings in Transcat were worth $30,467,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. BlackRock Inc. bought a new position in shares of Transcat in the second quarter valued at about $67,445,000. Barrow Hanley Mewhinney & Strauss LLC acquired a new position in Transcat during the 2nd quarter worth about $37,106,000. Wellington Management Group LLP acquired a new position in Transcat during the 2nd quarter worth about $29,409,000. Dimensional Fund Advisors LP grew its holdings in Transcat by 3.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 262,033 shares of the scientific and technical instruments company’s stock worth $19,244,000 after acquiring an additional 9,266 shares during the last quarter. Finally, Bamco Inc. NY bought a new stake in Transcat during the 2nd quarter worth about $17,649,000. 98.34% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have weighed in on TRNS shares. Northland Securities upgraded shares of Transcat from a “market perform” rating to an “outperform” rating and set a $95.00 price objective for the company in a research report on Wednesday, October 21st. Oppenheimer upgraded shares of Transcat from a “market perform” rating to an “outperform” rating and set a $115.00 target price on the stock in a research report on Wednesday. Weiss Ratings reiterated a “sell (d+)” rating on shares of Transcat in a research report on Tuesday, August 25th. Finally, CJS Securities assumed coverage on shares of Transcat in a research note on Tuesday, October 27th. They set an “outperform” rating and a $115.00 price target on the stock. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $108.33.

Transcat Stock Up 20.8%

NASDAQ TRNS opened at $108.13 on Thursday. The stock has a fifty day moving average of $86.49 and a 200-day moving average of $82.05. The stock has a market capitalization of $1.02 billion, a P/E ratio of 225.28 and a beta of 0.61. Transcat, Inc. has a 52 week low of $50.23 and a 52 week high of $110.47. The company has a debt-to-equity ratio of 0.36, a quick ratio of 2.11 and a current ratio of 2.49.

Transcat (NASDAQ:TRNS) last released its earnings results on Tuesday, November 3rd. The scientific and technical instruments company reported $0.64 earnings per share for the quarter, topping analysts’ consensus estimates of $0.45 by $0.19. Transcat had a return on equity of 6.18% and a net margin of 1.26%. The company had revenue of $97.09 million during the quarter, compared to the consensus estimate of $92.46 million. On average, equities research analysts forecast that Transcat, Inc. will post 1.79 EPS for the current year.

Insider Buying and Selling

In related news, Director Christopher P. Gillette sold 504 shares of Transcat stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $94.23, for a total value of $47,491.92. Following the completion of the sale, the director directly owned 200 shares in the company, valued at $18,846. This trade represents a 71.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.80% of the stock is currently owned by insiders.

Transcat News Summary

Here are the key news stories impacting Transcat this week:

• Positive Sentiment: Quarterly results beat expectations. Transcat reported adjusted earnings of $0.64 per share, ahead of analyst estimates of roughly $0.42–$0.45 and up from $0.44 a year earlier. Revenue of $97.09 million also exceeded the $92.46 million consensus. Article: Transcat Q2 earnings and revenues top estimates
• Positive Sentiment: Service growth and margins strengthened. The company raised its fiscal 2027 organic service-growth outlook to the low double digits and is targeting at least 100 basis points of service gross-margin expansion in the second half. Reports also pointed to service momentum and acquisitions as contributors to the quarter’s outperformance. Article: Transcat raises service growth outlook
• Positive Sentiment: Oppenheimer upgraded the stock. The firm raised its rating from “market perform” to “outperform” and set a $115 price target, adding to the favorable reaction to the results and outlook. Article: Oppenheimer stock recommendations

Transcat Profile

Transcat, Inc (NASDAQ: TRNS) provides calibration, compliance, and measurement services for organizations that rely on accurate test and measurement equipment. The company supports customers in regulated industries, including life sciences, aerospace and defense, energy, manufacturing, and other industrial markets.

Its service offerings include laboratory and onsite calibration, repair, validation, and asset-management services. Transcat calibrates a broad range of equipment used to measure temperature, pressure, electrical and electronic properties, radio frequency signals, dimensional characteristics, and other technical parameters.